Cantourage Group SE: Strategic Shift with 'gramz.' Launch

First Berlin Equity Research GmbH has released an updated research report on Cantourage Group SE. Analyst Ellis Acklin reiterated a "Buy" recommendation with a price target of €11. Cantourage has launched its first proprietary product, 'gramz.', for the German MedCan market, indicating a strategic shift away from its traditional revenue-sharing model for third-party flower products. Instead, the company will purchase raw materials outright, which is expected to increase margins.

The launch of 'gramz.' has shown promising initial sales results. This new product also expands the supplier base and allows Cantourage more control over product selection, pricing, and market positioning. Adjustments to Germany's MedCan reimbursement rules primarily affect the reimbursed flower segment, which comprises less than 10% of the market, having a minimal impact on Cantourage’s sales. The 2026 forecast anticipates an EBITDA margin of 11.5%, supporting the "Buy" stance.